Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUHAIL H KHADRA

NPI
1487603239
CMS profile
66653
Location
MUNSTER, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$292.38

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $292.38 14

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUHAIL H KHADRA

NPI 1487603239 · CMS profile ID 66653

MUNSTER, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487603239?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUHAIL H KHADRA, NPI 1487603239, CMS profile ID 66653. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487603239?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). SUHAIL H KHADRA, NPI 1487603239, CMS profile ID 66653. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487603239?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
SUHAIL H KHADRA, NPI 1487603239, CMS profile ID 66653, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1487603239?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $292.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $12.6511/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735857633 CMS
Esperion Therapeutics, Inc. $16.4810/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737215635 CMS
AstraZeneca Pharmaceuticals LP $17.7610/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736299681 CMS
Esperion Therapeutics, Inc. $14.7209/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737215631 CMS
Amgen Inc. $95.0009/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741324505 CMS
Amgen Inc. $15.4109/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741445857 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $17.1108/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723086333 CMS
Relypsa, Inc. $21.8707/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742178745 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $9.1107/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723086337 CMS
Lundbeck LLC $13.0807/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747539957 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $12.4007/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723086335 CMS
Relypsa, Inc. $19.7106/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742184491 CMS
E.R. Squibb & Sons, L.L.C. $12.1903/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727989449 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.8901/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720560995 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $540.50 20
PY2020 $292.38 14
PY2021 $543.76 36
PY2022 $794.26 44
PY2023 $994.78 34
PY2024 $913.91 39
PY2025 $621.54 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,061,757.66 207
PY2024 Principal investigator $654,195.55 69
PY2023 Principal investigator $594,110.73 53
PY2022 Principal investigator $288,215.55 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

207 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $5,465.01 12/31/2025 Non-covered Recipient Entity
Chicago Medical Research
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920326
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624924
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624926
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624928
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624930
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624932
Principal investigator 1 Boehringer Ingelheim International GmbH $61.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624934
Principal investigator 1 Boehringer Ingelheim International GmbH $2,496.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624936
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624938
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624940
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624942
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624944
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 12/15/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624946
Principal investigator 1 Janssen Research & Development, LLC $1,539.00 12/12/2025 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175212371
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $13,353.92 12/03/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,598.00 12/01/2025 Non-covered Recipient Entity
Chicago Medical Research, LLC
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508884
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9,500.00 12/01/2025 Non-covered Recipient Entity
Chicago Medical Research, LLC
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508908
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624920
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624922
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 12/01/2025 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175410752
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 12/01/2025 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175410758
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $20,030.88 11/26/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994193
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 11/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624898
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 11/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624900
Principal investigator 1 Boehringer Ingelheim International GmbH $128.00 11/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624902
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 11/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624904
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 11/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624906
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 11/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624908
Principal investigator 1 Boehringer Ingelheim International GmbH $2,496.00 11/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624910
Principal investigator 1 Boehringer Ingelheim International GmbH $2,496.00 11/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624912
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 11/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624914
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 11/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624916
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 11/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624918
Principal investigator 1 Janssen Research & Development, LLC $2,588.00 11/19/2025 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175212386
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,015.45 11/11/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994191
Principal investigator 1 Janssen Research & Development, LLC $3,320.00 11/07/2025 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175212402
Principal investigator 1 PFIZER INC. $1,617.00 11/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHEDCHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR PF07328948 IN ADULTS WITH HEART FAILURE BRANCHHF No dispute reported 06/30/2026 1228723622
Principal investigator 1 Janssen Research & Development, LLC $340.00 11/03/2025 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175212410
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624894
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624896
Principal investigator 1 PFIZER INC. $562.72 10/30/2025 Non-covered Recipient Entity
Chicago Medical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHEDCHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR PF07328948 IN ADULTS WITH HEART FAILURE BRANCHHF No dispute reported 06/30/2026 1228729712
Principal investigator 1 Boehringer Ingelheim International GmbH $2,797.20 10/27/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624948
Principal investigator 1 Boehringer Ingelheim International GmbH $2,190.00 10/27/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624950
Principal investigator 1 Boehringer Ingelheim International GmbH $43.50 10/27/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624952
Principal investigator 1 Boehringer Ingelheim International GmbH $37.60 10/27/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624954
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 10/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624890
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 10/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624892
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624864
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624866
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624868
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624870
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624872
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624874
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624876
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624878
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624880
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624882
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624884
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624886
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 10/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624888
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624860
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624862
Principal investigator 1 Boehringer Ingelheim International GmbH $3,396.60 09/24/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624852
Principal investigator 1 Boehringer Ingelheim International GmbH $2,920.00 09/24/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624854
Principal investigator 1 Boehringer Ingelheim International GmbH $52.20 09/24/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624856
Principal investigator 1 Boehringer Ingelheim International GmbH $56.40 09/24/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624858
Principal investigator 1 Janssen Research & Development, LLC $50,032.00 09/19/2025 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175212379
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $20,030.88 09/16/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994189
Principal investigator 1 Merck Sharp & Dohme LLC $66,939.40 09/08/2025 Non-covered Recipient Entity
Chicago Medical Research
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920324
Principal investigator 1 Organon Llc $5,762.40 09/08/2025 Non-covered Recipient Entity
Precision Trials AZ, LLC
1242-035 No dispute reported 06/30/2026 1173042574
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624832
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624834
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 08/26/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624850
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 08/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624840
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 08/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624842
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 08/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624844
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 08/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624846
Principal investigator 1 PFIZER INC. $15,843.00 08/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHEDCHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR PF07328948 IN ADULTS WITH HEART FAILURE BRANCHHF No dispute reported 06/30/2026 1228759757
Principal investigator 1 PFIZER INC. $2,762.21 08/02/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1228761732
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624828
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624830
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 07/28/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624848
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624780
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624782
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624784
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624786
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624788
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624790
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624792
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624794
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624796
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624798
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624800
Principal investigator 1 Boehringer Ingelheim International GmbH $2,496.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624802
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624804
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624806
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624808
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624810
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624812
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624814
Principal investigator 1 Boehringer Ingelheim International GmbH $1,427.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624816
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624818
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624820
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624822
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624824
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 07/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624826
Principal investigator 1 Amgen Inc. $73,213.81 07/23/2025 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246640209
Principal investigator 1 Janssen Research & Development, LLC $2,652.00 07/21/2025 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175410729
Principal investigator 1 Janssen Research & Development, LLC $5,016.00 07/18/2025 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175410740
Principal investigator 1 Janssen Research & Development, LLC $372.00 07/18/2025 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175410745
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624836
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624838
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624778
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 06/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624712
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 06/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624714
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 06/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624716
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 06/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624762
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 06/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624764
Principal investigator 1 Janssen Research & Development, LLC $7,456.00 06/13/2025 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175410735
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624718
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624720
Principal investigator 1 Boehringer Ingelheim International GmbH $2,496.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624722
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624724
Principal investigator 1 Boehringer Ingelheim International GmbH $2,496.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624726
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624728
Principal investigator 1 Boehringer Ingelheim International GmbH $61.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624730
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624732
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624734
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624736
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624738
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624740
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624742
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624744
Principal investigator 1 Boehringer Ingelheim International GmbH $1,427.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624746
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624748
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624750
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624752
Principal investigator 1 Boehringer Ingelheim International GmbH $1,427.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624754
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624756
Principal investigator 1 Boehringer Ingelheim International GmbH $1,427.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624758
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 06/04/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624760
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624708
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624710
Principal investigator 1 Boehringer Ingelheim International GmbH $399.60 05/27/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624776
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $16,692.40 05/20/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994185
Principal investigator 1 PFIZER INC. $382.05 05/13/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1228772354
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624704
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624706
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624674
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624676
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624678
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624680
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624682
Principal investigator 1 Boehringer Ingelheim International GmbH $61.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624684
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624686
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624688
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624690
Principal investigator 1 Boehringer Ingelheim International GmbH $2,496.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624692
Principal investigator 1 Boehringer Ingelheim International GmbH $2,496.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624694
Principal investigator 1 Boehringer Ingelheim International GmbH $2,496.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624696
Principal investigator 1 Boehringer Ingelheim International GmbH $2,496.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624698
Principal investigator 1 Boehringer Ingelheim International GmbH $2,496.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624700
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 04/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624702
Principal investigator 1 Boehringer Ingelheim International GmbH $599.40 04/23/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624766
Principal investigator 1 Boehringer Ingelheim International GmbH $1,533.00 04/23/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624768
Principal investigator 1 Boehringer Ingelheim International GmbH $23.49 04/23/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624770
Principal investigator 1 Boehringer Ingelheim International GmbH $4.65 04/23/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624772
Principal investigator 1 Boehringer Ingelheim International GmbH $34.78 04/23/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624774
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,692.19 04/23/2025 Non-covered Recipient Entity
Chicago Medical Research, Llc
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) No dispute reported 06/30/2026 1235998158
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624670
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624672
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 04/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994187
Principal investigator 1 Boehringer Ingelheim International GmbH $1,427.00 03/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624652
Principal investigator 1 Boehringer Ingelheim International GmbH $1,427.00 03/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624654
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 03/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624656
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 03/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624658
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 03/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624660
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624646
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624648
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 02/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624632
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 02/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624634
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 02/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624636
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 02/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624638
Principal investigator 1 Boehringer Ingelheim International GmbH $238.00 02/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624640
Principal investigator 1 Boehringer Ingelheim International GmbH $299.70 02/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624662
Principal investigator 1 Boehringer Ingelheim International GmbH $1,642.50 02/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624664
Principal investigator 1 Boehringer Ingelheim International GmbH $26.10 02/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624666
Principal investigator 1 Boehringer Ingelheim International GmbH $32.90 02/25/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624668
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $20,030.88 02/19/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994183
Principal investigator 1 Janssen Research & Development, LLC $8,584.00 02/19/2025 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175212395
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $165,123.00 02/18/2025 Non-covered Recipient Entity
Chicago Medical Research, Llc
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) No dispute reported 06/30/2026 1235998156
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624642
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624644
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624650
Principal investigator 1 Boehringer Ingelheim International GmbH $128.00 01/24/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624616
Principal investigator 1 Boehringer Ingelheim International GmbH $128.00 01/24/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624618
Principal investigator 1 Boehringer Ingelheim International GmbH $3,293.00 01/24/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624620
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 01/24/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624622
Principal investigator 1 Boehringer Ingelheim International GmbH $2,546.00 01/24/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624624
Principal investigator 1 Boehringer Ingelheim International GmbH $2,728.00 01/24/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624626
Principal investigator 1 Boehringer Ingelheim International GmbH $1,944.00 01/22/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624614
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8,346.20 01/16/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994181
Principal investigator 1 AstraZeneca Pharmaceuticals LP $105,421.30 01/08/2025 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185546169
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,234.99 01/08/2025 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 1185546171
Principal investigator 1 AstraZeneca Pharmaceuticals LP $100,168.53 01/03/2025 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185546167
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624628
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Chicago Medical Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220624630